Active Biotech AB Laquinimod Phase IIb Trial Confirms Efficacy And Favorable Safety Profile And Shows Significant Reduction In The Rate Of Inflammatory Disease Activity

LUND, SWEDEN -- (MARKET WIRE) -- September 05, 2006 -- The once-daily novel oral agent for relapsing remitting multiple sclerosis (MS) patients met its primary endpoint

MORE ON THIS TOPIC